Although drugs like methotrexate have traditionally been employed in treating lymphoplasmacytic lymphomas due to their cytotoxic properties and ability to cross the blood-brain barrier, recent support has emerged for ibrutinib, a Bruton tyrosine kinase inhibitor. Here, BTK is linked to lymphoplasmacytic lymphoma.